DMP Overzicht aandelen
Dermapharm Holding SE produceert en verkoopt samen met haar dochterondernemingen farmaceutische producten waarvan het octrooi is verlopen in Duitsland. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 3/6 |
Beloningen
Risicoanalyse
Dermapharm Holding SE Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €37.50 |
| 52 Week Hoogtepunt | €43.22 |
| 52 Week Laag | €30.15 |
| Bèta | 1.14 |
| 11 maand verandering | 17.92% |
| 3 maanden verandering | 4.90% |
| 1 Jaar Verandering | -8.00% |
| 33 jaar verandering | -53.01% |
| 5 jaar verandering | -0.40% |
| Verandering sinds IPO | 44.23% |
Recent nieuws en updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17Recent updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Rendement voor aandeelhouders
| DMP | DE Pharmaceuticals | DE Markt | |
|---|---|---|---|
| 7D | 10.3% | -7.0% | -0.4% |
| 1Y | -8.0% | -21.6% | 7.1% |
Rendement versus industrie: DMP overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -21.6 % opleverde.
Rendement versus markt: DMP presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.1 % opleverde.
Prijsvolatiliteit
| DMP volatility | |
|---|---|
| DMP Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stabiele aandelenkoers: DMP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van DMP is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, samen met haar dochterondernemingen, produceert en verkoopt merkfarmaceutische producten waarvan het octrooi is verlopen in Duitsland. Het bedrijf is actief in drie segmenten: Merkgeneesmiddelen en andere gezondheidsproducten, parallelimport en kruidenextracten. Het bedrijf biedt generieke merkgeneesmiddelen, OTC-producten, gezondheidsproducten zonder recept, kruidenextracten en parallel geïmporteerde originele geneesmiddelen.
Dermapharm Holding SE Samenvatting
| DMP fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €1.99b |
| Inkomsten(TTM) | €90.59m |
| Inkomsten(TTM) | €1.17b |
22.3x
Koers/Winstverhouding1.7x
P/S-verhoudingIs DMP overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DMP resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €1.17b |
| Kosten van inkomsten | €439.61m |
| Brutowinst | €734.32m |
| Overige uitgaven | €643.74m |
| Inkomsten | €90.59m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
Mar 28, 2025
| Winst per aandeel (EPS) | 1.68 |
| Brutomarge | 62.55% |
| Nettowinstmarge | 7.72% |
| Schuld/Eigen Vermogen Verhouding | 174.1% |
Hoe presteerde DMP op de lange termijn?
Bekijk historische prestaties en vergelijking